Sangamo Therapeutics downgraded by BofA Securities with a new price target

4/28/23 7:25:59 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

BofA Securities downgraded Sangamo Therapeutics from Neutral to Underperform and set a new price target of $1.50 from $5.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SGMO

Date	Price Target	Rating	Analyst
12/13/2024	$7.00	Hold → Buy	Truist
12/10/2024	$10.00	Buy	H.C. Wainwright
11/3/2023	$6.00 → $2.00	Outperform → Sector Perform	RBC Capital Mkts
4/28/2023	$5.00 → $1.50	Neutral → Underperform	BofA Securities
2/27/2023	$16.00	Neutral → Outperform	Wedbush
1/6/2023	$8.00 → $5.00	Buy → Neutral	BofA Securities
6/13/2022	$5.00	Neutral	Wedbush